INTELLECTUAL PROPERTY

ISSUED PATENTS

 

US 8,975,230 B2  & US 8,329,650 B2  Inventors: Walsh et al. Method of treating ischemic injury with follistatin-like 1 polypeptide. Abstract: Described herein are methods and compositions related to the discovery that the Follistatin-like 1 protein (Fstl-1) has metabolic and cardioprotective effects in vivo. Fstl-1 and portions and derivatives or variants thereof can be used to treat or prevent metabolic diseases or disorders and to treat or prevent cardiac damage caused by interrupted cardiac muscle blood supply.

 

US 10,149,922 B1 Inventors: Ruiz-Lozano et al. Engineered collagen matrices for myocardial therapy. Abstract: Disclosed is a patch system for use in a patient with a damaged heart. The patch comprises both a biodegradable engineered collagen scaffold to provide structural support to the injured heart and therapeutic agents, which are delivered by the patch to the heart. The scaffold consists of a dense collagen lamella produced by plastic compression with biomechanical properties that make it compatible with beating heart tissue, e.g. stiffness in a predefined range. One therapeutic agent, Fstl1, is shown to induce cardiomyocyte proliferation and enhance cardiac regeneration after injury. The patch can also be loaded with functionalized nanoparticles to yield multi-modal imaging capabilities in vivo. Also disclosed is a method for implanting the patch onto a patient's heart.

 

PATENT APPLICATIONS

WO 2016/164840 A1  Inventors: Ruiz-Lozano et al. Epicardial-derived paracrine factors for repairing cardiac tissue. Abstract. Provided herein, inter alia, are compositions and kits comprising epicardial-derived paracrine factors (such as, hypoglycosylated follistatin-like 1 (FSTL1)) for treating and repairing damage to cardiac tissue caused by cardiovascular disease, myocardial infarction (MI), other ischemic events, or cardiac-growth deficiency, as well as methods for using the same.

Highlights of these patent application: 

  • Composition of Matter, Pharmaceutical Compositions and Uses of Hypoglycosylated FSTL1

  • Clean ISR & WO by International Search Authority

  • Entered National Phase: US, Canada, Europe, Australia, Japan, China (Oct 9th, 2017)

  • Will provide COM protection for the API until at least 2035